EV-103 Study by Dr. Jonathan Rosenberg led to the FDA Approval of Enfortumab + Pembrolizumab
Автор: OncBrothers: Practice-Changing Cancer Discussions
Загружено: 2023-07-31
Просмотров: 1330
Описание:
Discussing the EV-103 Cohort K study, which resulted in the FDA approval of Enfortumab Vedotin + Pembrolizumab FDA Approval in the Cisplatin ineligible advanced urothelial carcinoma patients. In discussion with the lead author, Dr. Jonathan Rosenberg - Chief of Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center.
#immunotherapy #oncology #fda #enfortumab #pembrolizumab #2023 #cancer #oncbrothers
Website: http://www.oncbrothers.com/
Twitter: / oncbrothers
Contact us at [email protected]
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке: